Cargando…

A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort

Abdominal size is associated positively with the risk of some cancers but the influence of body mass index (BMI) and gluteofemoral size is unclear because waist and hip circumference are strongly correlated with BMI. We examined associations of 33 cancers with A Body Shape Index (ABSI) and hip index...

Descripción completa

Detalles Bibliográficos
Autores principales: Christakoudi, Sofia, Tsilidis, Konstantinos K., Evangelou, Evangelos, Riboli, Elio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366087/
https://www.ncbi.nlm.nih.gov/pubmed/34196490
http://dx.doi.org/10.1002/cam4.4097
_version_ 1783738838583083008
author Christakoudi, Sofia
Tsilidis, Konstantinos K.
Evangelou, Evangelos
Riboli, Elio
author_facet Christakoudi, Sofia
Tsilidis, Konstantinos K.
Evangelou, Evangelos
Riboli, Elio
author_sort Christakoudi, Sofia
collection PubMed
description Abdominal size is associated positively with the risk of some cancers but the influence of body mass index (BMI) and gluteofemoral size is unclear because waist and hip circumference are strongly correlated with BMI. We examined associations of 33 cancers with A Body Shape Index (ABSI) and hip index (HI), which are independent of BMI by design, and compared these with waist and hip circumference, using multivariable Cox proportional hazards models in UK Biobank. During a mean follow‐up of 7 years, 14,682 incident cancers were ascertained in 200,289 men and 12,965 cancers in 230,326 women. In men, ABSI was associated positively with cancers of the head and neck (hazard ratio HR = 1.14; 95% confidence interval 1.03–1.26 per one standard deviation increment), esophagus (adenocarcinoma, HR = 1.27; 1.12–1.44), gastric cardia (HR = 1.31; 1.07–1.61), colon (HR = 1.18; 1.10–1.26), rectum (HR = 1.13; 1.04–1.22), lung (adenocarcinoma, HR = 1.16; 1.03–1.30; squamous cell carcinoma [SCC], HR = 1.33; 1.17–1.52), and bladder (HR = 1.15; 1.04–1.27), while HI was associated inversely with cancers of the esophagus (adenocarcinoma, HR = 0.89; 0.79–1.00), gastric cardia (HR = 0.79; 0.65–0.96), colon (HR = 0.92; 0.86–0.98), liver (HR = 0.86; 0.75–0.98), and multiple myeloma (HR = 0.86; 0.75–1.00). In women, ABSI was associated positively with cancers of the head and neck (HR = 1.27; 1.10–1.48), esophagus (SCC, HR = 1.37; 1.07–1.76), colon (HR = 1.08; 1.01–1.16), lung (adenocarcinoma, HR = 1.17; 1.06–1.29; SCC, HR = 1.40; 1.20–1.63; small cell, HR = 1.39; 1.14–1.69), kidney (clear‐cell, HR = 1.25; 1.03–1.50), and post‐menopausal endometrium (HR = 1.11; 1.02–1.20), while HI was associated inversely with skin SCC (HR = 0.91; 0.83–0.99), post‐menopausal kidney cancer (HR = 0.77; 0.67–0.88), and post‐menopausal melanoma (HR = 0.90; 0.83–0.98). Unusually, ABSI was associated inversely with melanoma in men (HR = 0.89; 0.82–0.96) and pre‐menopausal women (HR = 0.77; 0.65–0.91). Waist and hip circumference reflected associations with BMI, when examined individually, and provided biased risk estimates, when combined with BMI. In conclusion, preferential positive associations of ABSI or inverse of HI with several major cancers indicate an important role of factors determining body shape in cancer development.
format Online
Article
Text
id pubmed-8366087
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83660872021-08-23 A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort Christakoudi, Sofia Tsilidis, Konstantinos K. Evangelou, Evangelos Riboli, Elio Cancer Med Cancer Biology Abdominal size is associated positively with the risk of some cancers but the influence of body mass index (BMI) and gluteofemoral size is unclear because waist and hip circumference are strongly correlated with BMI. We examined associations of 33 cancers with A Body Shape Index (ABSI) and hip index (HI), which are independent of BMI by design, and compared these with waist and hip circumference, using multivariable Cox proportional hazards models in UK Biobank. During a mean follow‐up of 7 years, 14,682 incident cancers were ascertained in 200,289 men and 12,965 cancers in 230,326 women. In men, ABSI was associated positively with cancers of the head and neck (hazard ratio HR = 1.14; 95% confidence interval 1.03–1.26 per one standard deviation increment), esophagus (adenocarcinoma, HR = 1.27; 1.12–1.44), gastric cardia (HR = 1.31; 1.07–1.61), colon (HR = 1.18; 1.10–1.26), rectum (HR = 1.13; 1.04–1.22), lung (adenocarcinoma, HR = 1.16; 1.03–1.30; squamous cell carcinoma [SCC], HR = 1.33; 1.17–1.52), and bladder (HR = 1.15; 1.04–1.27), while HI was associated inversely with cancers of the esophagus (adenocarcinoma, HR = 0.89; 0.79–1.00), gastric cardia (HR = 0.79; 0.65–0.96), colon (HR = 0.92; 0.86–0.98), liver (HR = 0.86; 0.75–0.98), and multiple myeloma (HR = 0.86; 0.75–1.00). In women, ABSI was associated positively with cancers of the head and neck (HR = 1.27; 1.10–1.48), esophagus (SCC, HR = 1.37; 1.07–1.76), colon (HR = 1.08; 1.01–1.16), lung (adenocarcinoma, HR = 1.17; 1.06–1.29; SCC, HR = 1.40; 1.20–1.63; small cell, HR = 1.39; 1.14–1.69), kidney (clear‐cell, HR = 1.25; 1.03–1.50), and post‐menopausal endometrium (HR = 1.11; 1.02–1.20), while HI was associated inversely with skin SCC (HR = 0.91; 0.83–0.99), post‐menopausal kidney cancer (HR = 0.77; 0.67–0.88), and post‐menopausal melanoma (HR = 0.90; 0.83–0.98). Unusually, ABSI was associated inversely with melanoma in men (HR = 0.89; 0.82–0.96) and pre‐menopausal women (HR = 0.77; 0.65–0.91). Waist and hip circumference reflected associations with BMI, when examined individually, and provided biased risk estimates, when combined with BMI. In conclusion, preferential positive associations of ABSI or inverse of HI with several major cancers indicate an important role of factors determining body shape in cancer development. John Wiley and Sons Inc. 2021-07-01 /pmc/articles/PMC8366087/ /pubmed/34196490 http://dx.doi.org/10.1002/cam4.4097 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Christakoudi, Sofia
Tsilidis, Konstantinos K.
Evangelou, Evangelos
Riboli, Elio
A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort
title A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort
title_full A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort
title_fullStr A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort
title_full_unstemmed A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort
title_short A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort
title_sort body shape index (absi), hip index, and risk of cancer in the uk biobank cohort
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366087/
https://www.ncbi.nlm.nih.gov/pubmed/34196490
http://dx.doi.org/10.1002/cam4.4097
work_keys_str_mv AT christakoudisofia abodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort
AT tsilidiskonstantinosk abodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort
AT evangelouevangelos abodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort
AT ribolielio abodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort
AT christakoudisofia bodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort
AT tsilidiskonstantinosk bodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort
AT evangelouevangelos bodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort
AT ribolielio bodyshapeindexabsihipindexandriskofcancerintheukbiobankcohort